Merck Acquires Cidara Therapeutics, Expands Portfolio with Late-Phase Antiviral Agent

Bassyonni

ago 2 hours

Merck Acquires Cidara Therapeutics, Expands Portfolio with Late-Phase Antiviral Agent

Merck has reached a definitive agreement to acquire Cidara Therapeutics, marking a significant move in its antiviral portfolio. The acquisition, valued at approximately $9.2 billion, is priced at $221.50 per share in cash.

Details of the Acquisition

Merck, through a subsidiary, is set to purchase all outstanding shares of Cidara. The deal conditions include approval from Cidara’s stockholders and regulatory reviews. Both companies’ boards have approved the transaction, which is anticipated to finalize in the first quarter of 2026.

Strategic Importance

This acquisition will enhance Merck’s respiratory pipeline, specifically with Cidara’s lead candidate, CD388. According to Robert M. Davis, Merck’s CEO, CD388 is a groundbreaking antiviral designed to prevent influenza, especially in individuals at higher risk for complications.

CD388: A drug-Fc conjugate aimed at preventing Influenza A and B.
Current Study: Evaluated in Phase 3 ANCHOR study with ongoing enrollment.
FDA Designation: Received Breakthrough Therapy and Fast Track Designation.

Clinical Trials and Efficacy

CD388 is currently being assessed in a Phase 3 trial targeting those at higher risk for flu complications. Previous studies have showcased its effectiveness in preventing symptomatic influenza in unvaccinated adults, achieving all trial goals in the Phase 2b NAVIGATE study.

Global Health Impact of Influenza

Influenza continues to affect millions worldwide, with an estimated 1 billion infections annually. It leads to approximately 290,000-650,000 deaths globally, particularly impacting older adults and immunocompromised individuals.

Future Outlook

Merck is poised to leverage its regulatory and commercial capabilities to advance CD388. Dr. Dean Y. Li of Merck highlighted the need for innovative solutions in influenza prevention.

Investor calls are scheduled, with further details on the acquisition to be available after the tender offer is initiated. This acquisition signifies a transformative milestone for both Merck and Cidara Therapeutics in the fight against influenza.